Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalised immunotherapy for cancer (PIC), has announced the initiation of its phase 2 randomised clinical trial in patients with high-risk hepatocellular carcinoma (HCC, liver cancer) who have undergone resection with curative intent. The trial is a multi-centre global trial with a planned enrolment of 90 patients.
PICs are targeted treatments that train a patient’s immune system to attack unique genetic mutations (neoantigens) found only in their specific tumour cells while sparing healthy tissue. The trial evaluates the efficacy of Geneos’ PIC (GNOS-PV02), compared to the current standard of care (active surveillance) in high-risk patients following surgery.
Additionally, the company announced the appointment of Julie Rosenberg MD, as Chief Medical Officer. Dr Rosenberg has more than two decades of leadership and drug development experience in the biopharmaceutical industry.
Dr Rosenberg completed her paediatric residency and haematology/oncology training at Baylor College of Medicine and has held leadership roles at major pharmaceutical companies – Boehringer Ingelheim, Bristol Myers Squibb, Bayer Healthcare and Pfizer.
She most recently served as Head of the Oncology Franchise for Linical, a mid-sized, global, contract research organisation. Dr Rosenberg joins Geneos at a pivotal stage, bringing her deep leadership and executive experience related to trial design, clinical development pathways, pharmacovigilance, medical strategy, operational efficiencies, regulatory submissions and more.
